Biotech
Top 2025 Biotech, MedTech, and Pharma Conferences You Can’t Miss
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Stay updated on the latest breakthroughs in biotechnology. From advancements in gene editing technologies like CRISPR to developments in cell and gene therapies, explore how biotech is driving medical innovation and transforming patient care.
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Quick Summary •Market Reaction: Biotech stocks saw modest gains following Trump’s 2024 election victory, reflecting optimism about regulatory leniency and M&A activity. •Key Appointments: Speculation
Quick Summary •Trend: AI-generated prior art is reshaping biotech patent law, challenging traditional approaches to intellectual property protection. •Key Issues: Authenticity, enablement, public accessibility, and
Quick Summary •Setback: Neurogene reported an adverse event in its high-dose gene therapy trial for Rett syndrome, involving liver toxicity and immune responses. •Key Issue:
Quick Summary Issue: The emergence of AI-generated prior art is disrupting traditional patent law. Key Impacts: Challenges include authenticity, public accessibility, and erosion of blocking
Quick Summary Event: Neurogene’s stock fell 44% after reporting a severe adverse event in its high-dose gene therapy trial for Rett syndrome. Clinical Concern: The
Quick Summary Clinical Data: Viking Therapeutics reported positive weight-loss results from trials of its oral obesity drug candidate. Market Reaction: Despite the positive clinical data,
Quick Summary Drug Development: Novo Nordisk plans to expand its obesity drug’s applications to treat metabolic-associated steatohepatitis (MASH). Clinical Findings: New trials indicate the drug’s
Quick Summary Election Outcome: Donald Trump’s recent victory is anticipated to bring major changes to U.S. healthcare and biotech regulation. Key Players: Trump has suggested
Quick Summary Election Outcome: The 2024 election could reshape U.S. biotech regulation, with different regulatory priorities depending on the administration. Kamala Harris’s Approach: Harris focuses